Citigroup Inc. is at the forefront of arranging a $2.45 billion debt financing deal for KKR & Co. Inc.'s acquisition of Integer Holdings, a medical-device manufacturer. This financing package includes $2.1 billion in funded debt, structured as a seven-year term loan, alongside a $350 million unfunded revolving credit facility.
Alongside Citigroup, other prominent financial institutions such as Barclays Plc, UBS Group AG, and Jefferies Financial Group Inc. are also participating in providing the debt for this transaction. This financial backing is crucial for KKR's estimated $5.7 billion acquisition of Integer Holdings.
Integer Holdings shareholders are set to receive $127 per share in cash, representing a substantial premium of approximately 51.8% over the company's closing share price on April 29, 2026, which was just before the announcement of a strategic review. The acquisition is anticipated to close by the end of 2026, pending shareholder and regulatory approvals. The Integer board has unanimously approved the agreement, and the transaction is not subject to any financing contingencies.
KKR intends to fund the acquisition through a combination of equity from its investment funds and committed debt financing. As a KKR portfolio company, Integer will gain increased flexibility and long-term capital for investments in capacity, technology, innovation, and talent, aiming to enhance its services for customers and patients globally. KKR also plans to implement a broad-based employee ownership program at Integer post-acquisition.
